A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Shoji T, Takatori E, Omi H, Kagabu M, Honda T, Futagami M, Yokoyama Y, Kaiho M, Tokunaga H, Otsuki T, Takano T, Yaegashi N, Kojimahara T, Ohta T, Nagase S, Soeda S, Watanebe T, Nishiyama H, Sugiyama T.
Shoji T, et al. Among authors: kojimahara t.
Cancer Chemother Pharmacol. 2017 Aug;80(2):355-361. doi: 10.1007/s00280-017-3363-0. Epub 2017 Jun 27.
Cancer Chemother Pharmacol. 2017.
PMID: 28656383
Free PMC article.
Clinical Trial.